Drugs / MUNC-T3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06736080 | May 2026 → Jan 2029 expected | familial hemophagocytic lymphohistiocytosis 3 | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUNC-T3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736080 ↗ |
| Action | Restore | “UNC13D LV Vector Expressing the UNC13D cDNA” NCT06736080 ↗ |
| Modality | Cell therapy | “transduced autologous T-cell” NCT06736080 ↗ |
| Route | Intravenous | “Route of administration: intravenous” NCT06736080 ↗ |
| Target | UNC13D | “UNC13D LV Vector Expressing the UNC13D cDNA” NCT06736080 ↗ |